Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Inclusion Criteria: * Age ≥ 18 years at the time of signing the informed consent form. * Have a life expectancy (in the opinion of the investigator) of at least 12 weeks. * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 (Karnofsky \> 60%). * History of previously treated MCL meeting the following criteria: Relapsed after or failed to respond to at least one prior line of systemic therapy including anti-CD20 monoclonal antibody and alkylator-containing chemotherapy. * At least one bi-dimensionally measurable nodal lesion ( \> 1.5 cm in its largest dimension by PET/CT scan), or at least one bi-dimensionally measurable extranodal lesion ( \> 1.0 cm in its largest dimension by PET/CT scan) and FDG-avid. * Availability of leftover tissue from the time of progression for pathology confirmation and correlative studies. Note: Formalin fixed paraffin embedded blocks are preferred. If blocks are not available, 12-15 slides containing unstained, serial sections are acceptable. * Hemoglobin ≥ 9 g/dL (Independent of transfusions and within 7 days prior to screening assessment). * Absolute neutrophil count \>= 1.0 x 10\^9/L (Independent of growth factor support and within 7 days prior to screening assessment). * Platelets ≥ 75 x 10\^9/L or \>= 50 x 10\^9/L if due to bone marrow involvement (Independent of transfusions and within 7 days prior to screening assessment, and independent of growth factor support and within 7 days prior to screening assessment). If the patient…